Precision Medicine for more Oxygen - COVID-19 extensio
Recruiting
- Conditions
- COVID-19
- Registration Number
- NL-OMON28553
- Lead Sponsor
- Amsterdam UMC, location AMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Age: 40-65 years.
-Proven ex-COVID-19: Positive PCR/serology for SARS-CoV2 or CORADS score 4/5.
-Able to provide informed consent.
-Access to internet (either at home or via relatives/friends).
-Understanding of Dutch language.
Exclusion Criteria
-Inability to provide informed consent.
-History or suspicion of inability to cooperate adequately.
-Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study or during the study.
-Investigator’s uncertainty about the willingness or ability of the patient to comply with the protocol requirements.
-Patients with terminal illness.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A.To assess pulmonary and extra-pulmonary damage (with imaging techniques), complaints (e.g. fatigue and Quality of Life) and other signs of disease (both clinical signs and multi-omics biomarkers) in the year after infection in ex-COVID-19 patients.<br>B.To assess whether a personalized counselling intervention on quality of dietary intake and level of physical activity can improve general health and decrease complaints and signs of disease (both pulmonary and extrapulmonary).
- Secondary Outcome Measures
Name Time Method -To determine the course of lung damage and complaints due to SARS-COV2 infection.<br>-To identify different phenotypes in ex-COVID-19 patients.<br>-To determine the influence of the exposome (environmental exposure) to lung damage and complaints in ex-COVID-19 patients one year post infection.<br>-To define different exposome-based groups at risk to develop lung damage after SARS-COV2 infection and subsequent hospitalisation.<br>-To assess the ability to use imaging techniques to detect lung damage in ex-COVID-19 patients without clear complaints. <br>-To determine whether SARS-CoV-2 infection triggers the onset of ME/CSF.<br>-To assess what risk factors are associated with the development of ME/CSF in ex-COVID-19 patients.<br>